(NASDAQ: DNTH) Dianthus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.15%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.
Dianthus Therapeutics's earnings in 2026 is -$173,660,000.On average, 16 Wall Street analysts forecast DNTH's earnings for 2026 to be -$208,699,278, with the lowest DNTH earnings forecast at -$271,078,916, and the highest DNTH earnings forecast at -$175,642,607. On average, 16 Wall Street analysts forecast DNTH's earnings for 2027 to be -$251,196,807, with the lowest DNTH earnings forecast at -$305,365,578, and the highest DNTH earnings forecast at -$198,028,429.
In 2028, DNTH is forecast to generate -$285,068,005 in earnings, with the lowest earnings forecast at -$321,437,450 and the highest earnings forecast at -$188,844,502.